A Phase III trial comparing either COntinuous chemotherapy plus cetuximab or INtermittent chemotherapy with standard continuous palliative combination chemotherapy with oxaliplatin and a fluoropyrimidine in first line treatment of metastatic colorectal cancer

Trial Profile

A Phase III trial comparing either COntinuous chemotherapy plus cetuximab or INtermittent chemotherapy with standard continuous palliative combination chemotherapy with oxaliplatin and a fluoropyrimidine in first line treatment of metastatic colorectal cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 25 Aug 2014

At a glance

  • Drugs Cetuximab (Primary) ; Capecitabine; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms COIN
  • Most Recent Events

    • 11 Jul 2011 Purpose, keywords, descriptors and study centers updated.
    • 08 Jun 2011 Results for XELOX or FOLFOX +/- cetuximab (groups A and B) published in Lancet
    • 03 Jun 2011 Results for continuous vs intermittent treatment (groups A and C) published in Lancet Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top